CD8A and neoplasm: In TME, ICs are co-inhibitors effectively engaged by tumour cells, immune cells, and stromal cells that bind to the ligands expressed on the cell surface of CD8+ T cells, triggering inhibitory signaling pathways and leading to the quiescence or exhaustion of CD8+ T cells (Palucka and Coussens, 2016).